Reference entry · Nonerythropoietic EPO helix-B–derived peptide
ARA-290
Also known as: ARA 290 · Cibinetide · EPO-derived repair peptide
- Class
- Nonerythropoietic EPO helix-B–derived peptide
- Size
- 11 amino acids
- Primary targets (literature)
- Innate repair receptor (EPOR/CD131 heteroreceptor literature)
- Regulatory context
- Investigational — not FDA-approved. Distinct from erythropoietic EPO and from connective-tissue catalog peptides.
Overview
ARA-290 is an EPO-derived peptide designed for tissue protection without erythropoiesis. Phase 2 data exist in diabetic neuropathy; not FDA-approved.
Mechanism in research literature
Selective innate repair receptor activation mediates anti-apoptotic and anti-inflammatory signaling in preclinical models without raising hematocrit like full EPO.
Common research focus areas
- Phase 2 type 2 diabetes neuropathy and corneal nerve endpoints
- Sarcoidosis neuropathy development literature
- Ischemia and nephrotoxicity preclinical protection models
- Short-peptide MS identity in catalog supply
Full literature roundup
Read the cited research summary
An EPO-derived nonerythropoietic peptide targeting innate repair receptor signaling. Phase 2 neuropathy data, tissue-protection literature, and RUO identity standards.
ARA-290 research roundup · 4 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.